It is therefore possible that GBM-derived heregulin-1β [11] (or other ERBB4 ligands, such as HB-EGF [47]) may promote resistance to EGFR-targeted therapies in a subset of GBM patients through compensatory ERBB4 signaling. This evidence concerns the gene ERBB4 and glioblastoma.